Podcasts about triple negative breast cancer

Host Melissa Berry sits down with Melissa Eppard, a triple negative breast cancer survivor and co-founder of Upstate Mary, a wellness brand focused on CBD-infused intimacy products. They talk about Melissa's personal breast cancer experience and the challenges many patients face with intimacy during and after treatment. Their conversation highlights the importance of addressing issues like vaginal dryness and the need for lubrication, which are often misunderstood, overlooked, and surrounded by shame. Melissa shares how CBD can help improve comfort and sexual wellness, while normalizing these conversations and taking the shame away. They also discuss the pressures both cancer survivors as well as their partners can feel around intimacy and the power of community support in reclaiming confidence and connection after cancer. This episode offers honest insights and encourages open conversations about sexual health for cancer survivors and their partners.

In today's powerful episode, I'm joined by Crissy, a vibrant, courageous woman who faced one of the most aggressive forms of breast cancer: triple negative breast cancer. What makes her story even more remarkable is that her symptoms were virtually silent. With no obvious warning signs, her diagnosis came as a complete shock.Crissy shares the emotional and physical rollercoaster of her treatment journey and how she coped with personal challenges. One of the most heartbreaking parts of her experience was having to put her IVF journey on hold, a dream of motherhood suddenly paused in the face of survival.We talk about the mental toll of navigating a life-altering diagnosis, how she found strength in the uncertainty, and what helped her stay grounded and hopeful throughout it all. Now cancer free, Crissy opens up about the importance of supportive care, and the self-love practices that helped her through her darkest days.This is a conversation about resilience, perspective, and the quiet power of tuning into your body. Crissy's story is a reminder to never ignore the whispers and to always hold on to hope.

Clinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer.  CME information and select publications here.

Featuring perspectives from Dr Aditya Bardia, Dr Virginia F Borges, Dr Harold J Burstein and Dr Joyce O'Shaughnessy, including the following topics: Introduction (0:00) HER2-Positive Breast Cancer — Dr O'Shaughnessy (3:13) Triple-Negative Breast Cancer — Dr Bardia (32:56) Personalizing Adjuvant Therapy for Patients with HR-Positive Breast Cancer — Dr Borges (57:35) Current Role of CDK4/6 Inhibitors in the Localized Setting — Dr Burstein (1:25:15) CME information and select publications

It's been known for many years that Black women are twice as likely as white women to be diagnosed with triple-negative breast cancer. If diagnosed with this type of breast cancer, Black women are also more than twice as likely to die from the disease than women of other races and ethnicities. Researchers have been studying a number of factors that may play a role in these disparities. Dr. Sanchita Bhatnagar's research has found that cells that have too much TRIM37 protein are much more likely to become cancerous. She and her colleagues also have found that the breast tissue of Black women are much more likely to have high levels of TRIM37. Listen to the episode to hear Dr. Bhatnagar explain: how she began studying the TRIM37 gene how a variant in the TRIM37 gene that causes more of the TRIM37 protein to be made is more common in Black women that white women how a medicine that targets the TRIM37 protein could help stop triple-negative breast cancer from metastasizing next steps for her research

In this special episode, I sit down with Ricki Fairley of TOUCH, The Black Breast Cancer Alliance and Hayley Dinerman of the Triple Negative Breast Cancer Foundation to discuss the latest advancements in TNBC research, including key takeaways from SABCS 2024, new immunotherapy and targeted therapies, and the impact of the AACR research grant. We also explore efforts to address racial disparities, upcoming awareness initiatives, and how you can get involved. Don't miss this insightful conversation about the future of TNBC treatment and advocacy. Thank you to Merck, Daiichi-Sankyo, Gilead, Pfizer, and Lilly for making this episode possible!  

About 10% to 15% of breast cancers are triple-negative. This means they don't have receptors for the hormones estrogen or progesterone, and don't have too many HER2 proteins. So, hormonal therapy medicines and medicines that target the HER2 protein aren't effective against triple-negative breast cancer.  Chemotherapy and immunotherapy are commonly used to treat triple-negative disease. But scientists are working diligently to develop new treatments that are more precise and targeted.  Triple-negative breast cancer expert Dr. Lisa Carey explains the latest research. Listen to the episode to hear Dr. Carey discuss: the two main areas of research on triple-negative breast cancer what antibody-drug conjugates are and their potential for treating triple-negative disease  the benefits of combining antibody-drug conjugates with immunotherapy the features of triple-negative breast cancer that make researchers think a vaccine for it is possible

Dinah McClymonds shares her journey with triple negative breast cancer and how regular mammograms detected her condition. She elaborates on her 2016 diagnosis and subsequent chemotherapy, surgery, and radiation, until she completed treatment a year later. Dinah had a positive experience with the medical care she received but acknowledges that many women lack such access. Her conversation with Dorothy highlights that early detection can significantly impact outcomes, even for those without a family history of the disease. She stresses the importance of mammograms and the need for broader access to these screenings, especially for uninsured women. Dinah also touches on her role as the chair for the 2025 Everything’s Coming Up Roses Luncheon supporting The Rose. Her background in fundraising and volunteering shapes her efforts to increase awareness and resources for those in need. Subscribe to Let’s Talk About Your Breasts wherever you get your podcasts and consider making a donation at therose.org. Key Questions Answered 1.) What prompted Dinah McClymonds to discuss breast cancer treatment and medical care? 2.) When and how was Dinah McClymonds's breast cancer diagnosed? 3.) How did her age and ethnicity influence her breast cancer treatment and prognosis? 4.) Did Dinah inform her family about her diagnosis, and how did genetic testing play a role for her identical twin? 5.) What is Dinah's message regarding early breast cancer detection and access to treatment? Timestamped Overview 00:00 Dinah to chair 2025 breast cancer luncheon. 03:33 Involvement in volunteer work with Kappa Alpha Theta. 09:06 Access to breast cancer treatment varies widely. 10:39 Challenging cancer diagnosis disrupts vacation plans. 14:06 Mammogram detected breast cancer, no symptoms noticed. 18:00 Unexplained triple negative, not hormonal, just fluke. 21:59 Effects of breast cancer treatment on body. 23:43 Accepting aging and medical treatment's inevitable impact. 29:04 Supporting access to early cancer detection and treatment. 30:11 Thank you for being our chair today.See omnystudio.com/listener for privacy information.

A young mom discovers a lump and learns she has triple negative breast cancer. She shares her journey and the supports she found from family, friends and faith.

It is Triple Negative Breast Cancer Day – an annual opportunity to bring more awareness to this aggressive type of breast cancer that is difficult to treat because it lacks an estrogen, progesterone and HER2 receptor. It primarily affects younger women and Black women and can spread quickly and be deadly if left untreated for too long. Treatment for TNBC used to include the toughest forms of chemotherapy, with debilitating side effects – but we've come a long way in how we treat patients with Triple Negative Breast Cancer so their outcomes are better. Today, we are speaking with Dr. Heather McArthur of UT Southwestern. She is a former Susan G. Komen grantee, Professor and the Komen Distinguished Chair in Clinical Breast Cancer Research. Dr. McArthur has been working on a Phase 3 clinical trial called KEYNOTE-522, which is testing whether a specific immunotherapy drug improves overall survival for people with high-risk early Triple Negative Breast Cancer. Dr. McArthur, along with her colleagues, are trying to determine if all people with this type of breast cancer truly need the drug, and if not, who would most benefit from taking it.

Metastatic Triple Negative Breast Cancer is one of the most challenging breast cancer subtypes to treat. Recurrence rates can be as high as 40%. This episode covers the role of immunotherapy and antibody-drug conjugates in the advanced space. Once again, targetable receptors are lacking but research is underway!Studies discussed in the episode:KEYNOTE 355ASCENTFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

It's all about love, and we need a lot of it, now more than ever. Please join me in welcoming my friend, Jennifer Greenhut aka @GreenhutTheBand, Stage IV Triple-Negative Breast Cancer Survivor, author, “Everyone Needs a Larry, Love with a Twist of Cancer,” and founder of the @ZeroNegativeOrg. Jennifer will talk about her journey with cancer, how she discovered she had Breast Cancer in the midst of trying to have a baby, and what ultimately saved her. She feels grateful, and for Valentine's Day, she's talking about spreading love and support for cancer patients with her “love totes” from @lovezeronegative, which are beautiful and proceeds support cancer research at the Johnson Cancer Center Foundation at UCLA. Oh, and there's more. Jennifer's parents and sister lost their homes in the Palisades fires, and they've all been pivoting to dealing with that tragedy, and she says there's lesson in all of that, too. And wait until you hear what survived!! Please join me on all video and audio platforms of #DeborahKobyltLIVE, and invite your friends, too. I'm your host, #DeborahZaraKobylt, and it's my pleasure to welcome you here

Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. To Get Cheryl's Book; https://www.amazon.com/dp/0190636165?linkCode=ssc&tag=onamzchefajsh-20&creativeASIN=0190636165&asc_item-id=amzn1.ideas.1GNPDCAG4A86S&ref_=aip_sf_list_spv_ofs_mixed_d_asin Cheryl Krauter,MFT an Existential Humanistic psychotherapist with 45 years of experience in the field of depth psychology and human consciousness. With her background in theater arts, working with performing artists, visual artists and creative people has inspired her. Her diagnosis of Triple Negative Breast Cancer in 2007 brought her into the world of psycho-oncology when she was asked to serve as a psychological consultant on a hospital survivorship plan task force. Committed to serving the community, she is a former board member of the Women's Cancer Resource Center in Oakland, California. She works with people who have been diagnosed with cancer and other life-threatening illnesses, their partners, family members, and caregivers from diagnosis to end of life care. She has published two books: Surviving the Storm: A Workbook for Telling Your Cancer Story (Oxford University Press 2017) and Psychosocial Care of Cancer Survivors: A Clinician's Guide and Workbook for Providing Wholehearted Care (Oxford University Press 2018). Her book Odyssey of Ashes: A Memoir of Love, Loss, and Letting Go, She Writes Press, was released in July 2021. Her piece With This Ring is published in Loss and Grief: Personal Stories of Doctors and Other Healthcare Professionals (Oxford University Press 2022). Cheryl has been a member of the American Psychosocial Oncology Society (APOS)and the International Psychosocial Oncology Society (IPOS) since 2014. She has served as the Director of Communications for the American Psychosocial Oncology Society since 2023 and was honored to receive the APOS Distinguished Public Service Award in 2022. Cheryl has given workshops and classes at The Women's Cancer Resource Center (Oakland, CA), The Cancer Support Community (Walnut Creek and Los Angeles, CA), University of California, Berkeley, University of California, San Francisco Cancer Center, The American Psychosocial Oncology Society, San Francisco State University, Casting for Recovery, Swedish Cancer Center (Seattle WA), Northern California Group Psychotherapy Society, Alta Bates Hospital (Berkeley, CA) You may find resources, podcasts, interviews, articles, webinars on her website. www.cherylkrauter.com Surviving the Storm: Finding Resilience and Discovering Possibility When Facing a Cancer Diagnosis “It only takes a few seconds to receive the news that you have been diagnosed with cancer. Yet, from that point on your world has been changed forever. You enter a vast terrain of uncertainty, isolation and insecurity when you finish treatment for cancer. What is it like to face daily life now that you are finished with treatment? Fear of recurrence, anxiety and depression related to uncertainty, along with loss and financial difficulties, as well as concerns around sexuality are all a part of this new territory. You may feel alone and distressed. You have all the knowledge within you to understand and create your own healing but sometimes you need guidance to help you find where you are and support you in discovering where you want to go.” Excerpt from Surviving the Storm: A Workbook for Telling Your Cancer Story by Cheryl Krauter, MFT Let's build a conversation on how those who have been diagnosed with cancer can find ways to thrive and engage meaningfully in their lives as they navigate their diagnosis.

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Virginia Kaklamani from the UTHealth San Antonio MD Anderson Cancer Center to discuss the latest advances in the treatment of triple negative breast cancer (TNBC) as we kick off 2025. •⁠  ⁠The treatment paradigms for early-stage TNBC, including the role Sacituzumab and radiation therapy. •⁠  ⁠Insights from the SABCS 2024 conference, focusing on the keynote 522 regimen and its implications for neoadjuvant treatment. •⁠  ⁠The management of locally advanced and metastatic TNBC, including the use of immunotherapy and the importance of PD-L1 testing. •⁠  ⁠Strategies for managing toxicities associated with treatments like sacituzumab and T-DXd. Whether you're a healthcare professional or someone interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! Key Takeaways: •⁠  ⁠Current standard of care for locally advanced TNBC. •⁠  ⁠The significance of chemotherapy and immunotherapy in treatment plans. •⁠  ⁠Managing toxicities in metastatic disease. Stay tuned for more discussions on treatment algorithms, FDA approvals, and clinical pearls in oncology! YouTube: https://youtu.be/GfROoYPVb_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

Early Triple Negative Breast Cancer remains an aggressive variant of all breast cancers, affecting those under 40 more and has a higher propensity for being in those with BRCA1/2 mutations. It represents about 15% of all breast cancers.This week, we explore the benefit of immunotherapy (pembrolizumab), looking at improved complete pathological response as a surrogate marker for OS and the role of capecitabine in the adjuvant setting.Studies discussed in the episode:CREATE-XKEYNOTE-522For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

Dr. Jeanine Cook Garard meets Carly Fauth, a triple-negative breast cancer survivor, fitness professional, host of the Chemo Coffee Talk podcast and now author of the book, Pray for the Bear: An Ordinary Person's Guide to Unlocking Extraordinary Personal Strength.  She is on a mission to turn lemons into lemonade, aimed at helping others through cancer.

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from January 25-31, 2025.

Today's witnesses are from Matthew West's website called popwe.org. If you don't know who Matthew West is, he is a singer, songwriter, and storyteller. This website is for the non-profit that he has with his father, a pastor. Matthew and his father encourage people to share their stories. They have various categories of stories. Today, I chose two testimonies from the Healing Category. Often, we can hear our own story in someone else's story. When we listen to others tell their story, it helps us see that we are not alone. When we hear how God worked in their situation, it gives us hope that He will work in ours, too! I pray when you hear these testimonies, you get the faith and hope to believe that miracles can happen in your situation, also. I pray you know that God is there with you, and if you invite Him into your situation, He can help. I hope you enjoy these testimonies.Karen:  In 2004 my mom suffered kidney failure and started dialysis at 75. It was very hard on her while my older sister tested to be a donor and was ruled out. Then my older brother tested and was unable to donate. It's important to note that they are both biological children and I was adopted. I was also a single mom raising two kids at 37, so needless to say I was scared to donate, but I prayed and my growth group prayed with me. Come to find out, a man sitting beside me had donated his kidney to his daughter and was doing great 18 years later. I also kept seeing signs to remind me that “greater love hath no man than to lay down his life for another,” so I stepped up and was deemed acceptable but had to lose 40 pounds to do so.Mom was getting more drained by the day. I lost the weight in 8 weeks and surgery was scheduled for October, but mom suffered a hematoma and surgery was put off till February for her healing. The waiting was tough. It made me second guess but I still did it.  In February 2005, she was able to stop dialysis after I donated my kidney to her and my prayer was that God would take care of us. It's because of seeing the toll mom and my grandma went through on dialysis I knew I could never do that. Lesson learned. Never tell God what you can't do!Fast forward 14 years. I got kidney cancer and had a partial nephrectomy in September of 2019. Unfortunately surgery had complications and I had a collapsed lung, respiratory distress, and internal bleeding that resulted in a 34 day hospital stay including a medically induced coma for 2 weeks. My family was unsure if I would make it or not. I remember asking God to take me as I was on a ventilator and unconscious, but He said it wasn't my time yet, He had great plans for me. My kids still needed me so I asked Him to heal me. Within 2 days I was awake, and the next day the ventilator came out. A few days after that I left ICU for a regular room. That only lasted 2 days before being discharged to rehab for 2 weeks where I learned how to walk again.Unfortunately, my kidney never woke up after that surgery even though I still had 78% left, but they think the medications they gave me for the coma were too strong and could have damaged it further. Thus began my time on dialysis and boy was it miserable. Three times a week I would go in and be hooked up to a life-saving machine for 3 hours, then be exhausted after with muscle cramps, nausea, high blood pressure, headaches, and overall feeling miserable. I had numerous surgeries for peritoneal dialysis but it never worked. I had numerous hospital stays for high blood pressure, headaches, abdominal pain, and bowel obstructions. It was the roughest 33 months of my life.I was finally approved for a transplant in April of 2022 and on Mother's Day May 8, 2022 I got a new kidney! Praise God for only He could schedule that! After giving my mom a kidney in 2005, He gave me one on Mother's Day- amazing! It's now several months later and although it hasn't been a picnic I am so thankful to be on the road to health and healing. Blessed be the name of the Lord!We celebrated my parents 69th wedding anniversary this past Sunday and I'm so thankful for all that God has done and continues to do on a daily basis for me! To God be the glory!Emily:  Hello, I'm Emily. I'm a 10 time Breast Cancer Survivor. Yes, you read that right, ….TEN.It all began with a stomach ache in 2008. As I went to my doctor for a routine exam, she found the Cancer! Of course, I had to go through an ultrasound and mammogram first, but my doctor had saved my life by detecting this early, I thought.I was 33, had 3 kids, (ages 6, 2, and 8 months) and a full-time job teaching 1st graders at a public school. Cancer? Who has time for Cancer? I was told it is an aggressive form and difficult to treat, because doctors don't know much about it. I have Triple Negative Breast Cancer. I fought with everything I had through chemo, radiation and a lumpectomy.God and I spent a lot of time talking about how I was going to win this battle and with His help, I did, for 4 1/2 years.The Demon itself returned in March of 2012, just before my 5 year clear mark. I was devastated, scared, angry, frustrated and MAD at God. Why was this happening to me again? Why do I have to go through this again? This isn't fair! God carried me through the second battle, just as He did the first with just as much grace and comfort.Fast-forward to 2022. I've now had TWO double mastectomies, a lumpectomy, ten biopsies, a DIEP flap reconstruction surgery, 3 more rounds of chemo (78 total treatments), 3 different types of radiation (67 total treatments), and Proton therapy (35 treatments) to try and kill this cancer. It has reared its ugly head 10 times and this is going to be the last!!!Just a month and a half ago, I learned about a new drug that people were having success rates with. It was a Godsend and true miracle. An email delivered to my inbox revealed something we've been waiting for for 15 years!!!! The product is working and I will have another scan in February to hear that there is NED (No evidence of disease)!!! I am positive after reading the success stories!I tell my story to say this… God is the only reason I am still here!!!! Nobody survives Cancer 10 times without God. Period.  If you are battling Cancer of any kind, just know that God is on your side and He is the ultimate healer!!!! Without Him and our faith, we are nothing!! I'm still standing AND teaching for 15 years and 10 battles later!God is so good and Matthew West, you're my favorite!!! Your music inspires me and the children in my class from rough homes every single day!! Our favorite is “How Good Of God!”Thank you both so much for sharing your stories. I know it can be hard to be vulnerable and share your story with other. When you are able to do so though it helps other people see they are not alone. It provides hope to those who hear it. Thank you!  www.findingtruenorthcoaching.comCLICK HERE TO DONATECLICK HERE to sign up for Mentoring CLICK HERE to sign up for Daily "Word from the Lord" emailsCLICK HERE to sign up for my newsletter & receive a free audio training about inviting Jesus into your daily lifeCLICK HERE to buy my book Total Trust in God's Safe Embrace

Featuring perspectives from Dr Lisa Carey and Dr Rita Nanda, including the following topics: Introduction (0:00) Patient Videos and Clinical Investigator Survey (3:26) San Antonio Breast Cancer Symposium (SABCS®) Report — Education Session on Antibody-Drug Conjugates (26:03) Patient Videos and Clinical Investigator Survey (43:27) SABCS Report — Abstracts of Interest (55:56) Patient Videos and Clinical Investigator Survey (56:27) CME information and select publications

Dr Lisa A Carey from UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from the University of Chicago in Illinois address commonly asked questions from patients diagnosed with metastatic triple-negative breast cancer. CME information and select publications here

Dr Lisa A Carey from UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from the University of Chicago in Illinois address commonly asked questions from patients diagnosed with metastatic triple-negative breast cancer. CME information and select publications here

In this enlightening episode of the Patient From Hell, host Samira Daswani interviews Dr. Sara Tolaney, a leading oncologist specializing in breast cancer. They delve into the evolving landscape of triple-negative breast cancer (TNBC), exploring advancements in treatment, from targeted therapies to immunotherapy, and the challenges faced by patients in both early-stage and metastatic settings. With her characteristic warmth and expertise, Dr. Tolaney provides actionable insights for patients and caregivers, offering hope and understanding in navigating this complex diagnosis. Key Highlights: 1. A New Paradigm in Early-Stage TNBC Treatment: Dr. Tolaney explains how neoadjuvant chemotherapy combined with immunotherapy has revolutionized outcomes, achieving pathologic complete response rates above 60%. 2. Metastatic TNBC Advances: The discussion highlights the critical role of biomarker testing and the introduction of innovative therapies like antibody-drug conjugates, providing extended survival for many patients. 3. Empowering Patient Symptom Management: The episode underscores the importance of patient-reported outcomes and emerging tools like health apps to enhance self-management and real-time support for side effects. About our guest: Sara Tolaney, MD, MPH is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and is internationally recognized for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women's Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Dr. Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Masters in Public Health from Harvard School of Public Health. Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals such as the New England Journal, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology. Key Moments: At 8 minutes: "It used to be that if someone had a triple negative breast cancer, we would often take someone to surgery and then after surgery give them some chemotherapy to kill any stray cells that might've gotten into the bloodstream and integrate radiation as needed. But we've really changed our approach very dramatically over the last few years where we've learned that if someone has an early stage, stage two or three triple negative breast cancer, it is actually very critical that they not go to upfront surgery, but in fact get chemotherapy with immunotherapy prior to surgery." Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics:  Introduction (0:00) Stages of Triple-Negative Breast Cancer (TNBC); Recurrence After Adjuvant Treatment (5:28) Long-Term Outcomes with Metastatic TNBC (11:55) Side Effects and Complications of Treatment (24:42) Dose Reduction (30:27) Working While Receiving Treatment (32:24) Support for Minor Children and Grandchildren (37:12) Second Opinions and Self Advocacy (42:53) Recording Clinic Visits; Complementary Therapies; Nutrition (48:38) Living Wills and Advanced Directives (55:41) Please take our survey

For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill and Dr Rita Nanda from The University of Chicago to discuss the patient experience associated with the diagnosis and treatment of metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. Select publications here (https://www.researchtopractice.com/PatientProject2024/mTNBCPatients).

For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill and Dr Rita Nanda from The University of Chicago to discuss the patient experience associated with the diagnosis and treatment of metastatic triple-negative breast cancer.

- The Treatment of Triple Negative Breast Cancer - Why Clinical Trials are Important as a Treatment Option for Triple Negative Breast Cancer - What Happens in a Clinical Trial - Stages of Clinical Trials - New Research in the Treatment of Triple Negative Breast Cancer (TNBC) - Investigational New Drugs in Clinical Trials - The Meaning of Informed Consent - Benefits & Risks of Participation - How & Where Clinical Trials are Conducted - How to Participate in Clinical Trials - Specific Questions to Ask Your Health Care Team about Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Accessing Resources for Clinical Trials - Questions for Our Panel of Experts

- The Treatment of Triple Negative Breast Cancer - Why Clinical Trials are Important as a Treatment Option for Triple Negative Breast Cancer - What Happens in a Clinical Trial - Stages of Clinical Trials - New Research in the Treatment of Triple Negative Breast Cancer (TNBC) - Investigational New Drugs in Clinical Trials - The Meaning of Informed Consent - Benefits & Risks of Participation - How & Where Clinical Trials are Conducted - How to Participate in Clinical Trials - Specific Questions to Ask Your Health Care Team about Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Accessing Resources for Clinical Trials - Questions for Our Panel of Experts

- The Treatment of Triple Negative Breast Cancer - Why Clinical Trials are Important as a Treatment Option for Triple Negative Breast Cancer - What Happens in a Clinical Trial - Stages of Clinical Trials - New Research in the Treatment of Triple Negative Breast Cancer (TNBC) - Investigational New Drugs in Clinical Trials - The Meaning of Informed Consent - Benefits & Risks of Participation - How & Where Clinical Trials are Conducted - How to Participate in Clinical Trials - Specific Questions to Ask Your Health Care Team about Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Accessing Resources for Clinical Trials - Questions for Our Panel of Experts

Maimah Karmo shares her story with triple-negative breast cancer and how she founded the Tiger Lily Foundation. Maimah emphasizes the importance of self-advocacy, community support, and education in traversing healthcare challenges. She shares her experience of being dismissed by doctors due to her age and ethnicity, and how this motivated her to create an organization that empowers women of color facing similar struggles. Key Highlights: 1. Trust your gut, it could save your life. 2. Don't do it alone, community is what will help you do what you need to do even if you're afraid. 3. Be the best advocate you can be for yourself, this is your life and your body – you are worth  the fight. About our guest: Maimah Karmo is the Founder/CEO of the Tigerlily Foundation (Tigerlily) and an eighteen-year survivor of breast cancer. On February 28, 2006, at 4:45 p.m., Maimah was diagnosed with Stage 2 triple negative breast cancer. She had no family history and was 32-years old.  While undergoing her second round of chemotherapy, she made a promise to God that if she survived, she would create an organization to educate, empower, advocate for and support young women affected by breast cancer.  A first-generation immigrant from Liberia, who has experienced disparities first-hand, she is a leader in the women's health field, creating and implementing national health initiatives for women and girls, with a goal of eliminating disparities of age, stage and color.  Under Maimah' s leadership, Tigerlily Foundation has launched national and global health initiatives focused on ending disparities, through the #InclusionPledge, partnering with global stakeholders, with a call to action to recognize health disparities as a social justice issue; and working to end disparities for black women in our lifetime. She is a global thought leader, health advocate and philanthropist, committed to justice and equity for all. Maimah also works directly with women and their families to connect the patient with better care and knowledge. through events such as the Annual Young Women's Breast Health Day on the Hill and other philanthropic efforts and successful educational and support programs.  You can find Maimah on Twitter, on Instagram, and on Facebook.  Check out the Tigerlily Foundation here. Key Moments: At 6 minutes 25 seconds “I ended up finding the flower one day, the tiger lily… It's like a woman, beautiful, different layers to her, and also when people are going through treatment there's a sense of so much fear. You do lose things in a way. You may lose your petals: your hair, eyebrows, eyelashes, breasts, other parts of your body, male or female. The flower is a perennial, so in the fall, winter, the petals fall off but in the spring and summer, they blossom again.  I want people who are coming to Tigerlily to feel that sense of: I'm going through this time of dormancy and things are falling off, but that means I could grow and transform into something beautiful and amazing and just badass.You could find beauty, strength and be transformed throughout the cancer journey.” Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only.  This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

- Overview of Triple Negative Breast Cancer - New Research on TNBC Presented at SABCS - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Triple Negative Breast Cancer - New Research on TNBC Presented at SABCS - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Triple Negative Breast Cancer - New Research on TNBC Presented at SABCS - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients with Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial." Related Content: Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer

New research suggests that estrogen plays a role in allowing hormone receptor-negative breast cancer to grow. This is because estrogen limits the ability of the immune system to attack cancer cells; it also makes immunotherapy medicines, like Keytruda (chemical name: pembrolizumab), less effective. Dr. Donald McDonnell, senior author of the study, explains the results and how they might make a difference for people with breast cancer. Listen to the episode to hear Dr. McDonnell explain: what eosinophils are and how he started studying them in connection with breast cancer how estrogen in the body affects the immune system how a hormonal therapy medicine, like tamoxifen, can make an immunotherapy medicine, like Keytruda, more effective

Featuring perspectives from Dr Priyanka Sharma and Dr Sara M Tolaney, including the following topics: Introduction: Metastatic Triple-Negative Breast Cancer (mTNBC) — The Patient Perspective (0:00) Selection and Sequencing of Antibody-Drug Conjugates (5:09) Dosing and Tolerability of Sacituzumab Govitecan; Use of Anthracyclines (14:39) Case: A woman in her early 60s with relapsed TNBC (HER2 2+) who experiences disease progression on T-DXd (Grade 2 interstitial lung disease) and receives sacituzumab govitecan — Shaachi Gupta, MD, MPH (22:04) Discussing Palliative and End-of-Life Care (32:40) PARP Inhibitors for TNBC with Somatic versus Germline Mutations; Cytopenias with PARP Inhibitors (37:53) The “Art of Oncology” — Building Trust with Patients and Family Members (45:05) Case: A woman in her mid 60s with recurrent TNBC with extensive chest wall involvement — Dr Gupta (48:44) Case: A man in his mid 40s with multiregimen-refractory AR-positive TNBC with an ERBB2 exon 20 insertion mutation — Dr Gupta (52:53) CME information and select publications

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer.

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.Launch Date: December 5, 2024Release Date: December 5, 2024Expiration Date: November 30, 2025FACULTYAditya Bardia, MD, MPH, FASCOAssociate Professor, Medicine, Harvard Medical SchoolAttending Physician, Medical Oncology, Massachusetts General HospitalDana-Farber/Harvard Cancer Center, Boston, MARita Nanda, MDAssociate Professor of MedicineDirector, Breast Oncology ProgramThe University of Chicago Medicine Chicago, ILThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.Launch Date: December 5, 2024Release Date: December 5, 2024Expiration Date: November 30, 2025FACULTYAditya Bardia, MD, MPH, FASCOAssociate Professor, Medicine, Harvard Medical SchoolAttending Physician, Medical Oncology, Massachusetts General HospitalDana-Farber/Harvard Cancer Center, Boston, MARita Nanda, MDAssociate Professor of MedicineDirector, Breast Oncology ProgramThe University of Chicago Medicine Chicago, ILThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.Launch Date: December 5, 2024Release Date: December 5, 2024Expiration Date: November 30, 2025FACULTYAditya Bardia, MD, MPH, FASCOAssociate Professor, Medicine, Harvard Medical SchoolAttending Physician, Medical Oncology, Massachusetts General HospitalDana-Farber/Harvard Cancer Center, Boston, MARita Nanda, MDAssociate Professor of MedicineDirector, Breast Oncology ProgramThe University of Chicago Medicine Chicago, ILThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/FCS2024mTNBC).

Get your FREE copy of “Your A-Z Guide to Staying Cancer Free” here: https://bit.ly/azcancerfree New Research! New findings were released on the Triple Negative Breast Cancer Vaccine.   This is starting to sound promising.   Of course vaccines are quite controversial. But triple negative has such few treatment options so it's always nice to see more development.  More treatment options is always a good thing.  So if you are a triple negative breast cancer survivor or at high risk of developing breast cancer, this video is for you! So let me show you how it's done.   Join the Cancer Freedom Program Click HERE www.cancerfreedomprogram.com   #cancerfighter #cancersurvivor #breastcancer #breastcancersurvivors #cancerrecovery  #cancernutrition #mastectomy #tamoxifen #anastrozole #letrozole #exemestane    ***PS - Whenever you're ready, here are the 2 best ways I can help you… 1) “Your A-Z Guide to Staying Cancer Free” **FREE** Click HERE https://bit.ly/azcancerfree   2) Join the Cancer Freedom Program Click HERE www.cancerfreedomprogram.com   ***Let's Connect: Website: www.cancerfreedomprogram.com Instagram: https://www.instagram.com/dramymorris/ YouTube: https://www.youtube.com/channel/UCUt9... Facebook: https://www.facebook.com/dramycancer/

Learn how to kick out chemo symptoms with fitness led by Carly Fauth of Fit Fun Carly. “Fit Fun Carly” has taught over 4,000 fitness classes of all types and has dedicated her life to EVERYbody find joy and fun in fitness. And then, in February, she was diagnosed with Triple Negative Breast Cancer. She pushed through 16 weeks of aggressive chemo (and started her podcast: "Chemo Coffee Coffee Talk" on Spotify right from the chemo chair!) and discovered just how much exercise can kick out miserable chemo symptoms—even when it's the last thing you want to do! Tune it in to learn how to be “fit for the fight” and discover joy in movement!  For more tools to support your healing journey, grab a copy of Heal Breast Cancer Naturally—a comprehensive guide that includes supportive supplements and holistic processes for healing, including insights for Triple Negative Breast Cancer like Carly experienced. Or explore our Matcha Green Tea or DIM supplements, specifically chosen for their ability to support detoxification and hormone balance during recovery.

In December 2023, Charity Kelchen of Iowa was given only weeks to live, facing the devastating reality of stage 4 triple-negative breast cancer, compounded by a painful, fungating tumor. Placed on hospice care, she endured months of severe bleeding and blood loss until doctors removed an 8-pound tumor from her chest. But her battle was far from over—new, aggressive tumors emerged, forcing her through 40 grueling days of radiation. Amid the relentless fight, Charity turned to cannabis oil, an unconventional yet powerful tool in her recovery. On October 10th, 2024, she received the news she had fought so hard for—a clean scan. Visit our website: CannabisHealthRadio.comFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

In 1999 Saranne was diagnosed with stage IV triple negative breast cancer. After being misdiagnosed by 11 doctors over 6 years, she had 3 surgeries, 44 radiation treatments and 2+ years chemotherapy (up to 3x daily). It was then determined that her type of cancer was non-responsive to chemo and she was told to get her affairs in order. And this is when Saranne began researching how to reinvent her immune system. While she took a multifaceted approach using all the healing factors, she attributes the "increasing positive emotions" healing factor to be the one that played the strongest role in her healing. 25 years later, Saranne is still cancer-free. She launched The ComedyCures Foundation from her chemo chair in 1999 to help others rediscover their funny bone, mojo, and purpose. She hosts The Beating Cancer Daily Podcast combining a unique blend of humor and wellness strategies. The ComedyCures Foundation https://www.ComedyCures.org Beating Cancer Daily: A Bite-sized Podcast with Stage IV cancer survivor Saranne Rothberg https://www.comedycures.org/bcdpodcast 24-Hour Free LaughLine 1-888-HA-HA-HA-HA (1-888-424-2424) @ComedyCures @SaranneLive #BeatingCancerDaily ______ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram  YouTube

Featuring an interview with Dr Tiffany A Traina, including the following topics: Choice of chemotherapy to combine with first-line pembrolizumab for metastatic triple-negative breast cancer (mTNBC) (0:00) Ongoing investigations of androgen receptor-targeting agents for metastatic breast cancer (mBC) (8:37) Efficacy and CNS activity of sacituzumab govitecan for mTNBC; monitoring and management of treatment-associated side effects (14:34) Activity and tolerability of enfortumab vedotin for mTNBC (21:47) Rationale for combining antibody-drug conjugates with other systemic therapies for TNBC; early data and ongoing research efforts with combination approaches (24:13) Selection and sequencing of therapeutic options for advanced breast cancer (26:36) Clinical activity of trastuzumab deruxtecan; spectrum, severity and management of treatment-emergent toxicities (32:00) Case: A woman in her early 60s with mTNBC receives first-line pembrolizumab/carboplatin/gemcitabine (35:32) Case: A woman in her late 30s with TNBC and a short disease-free interval with adjuvant therapy is found to have CNS metastases that are treated with sacituzumab govitecan (40:40) Case: A woman in her late 60s and practicing physician is diagnosed with HR-negative, HER2-low mBC (44:16) CME information and select publications

Featuring a slide presentation and related discussion from Dr Tiffany A Traina, including the following topics: Extended follow-up with pembrolizumab/chemotherapy for patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC) (0:00) ASCENT trial: Survival advantage with sacituzumab govitecan versus physician's choice of chemotherapy for patients with relapsed/refractory TNBC (2:49) Treatment-associated side effects with sacituzumab govitecan (5:32) Activity of sacituzumab govitecan irrespective of TROP2 expression level and in patients with brain metastases (6:48) Ongoing Phase III studies evaluating sacituzumab govitecan in earlier lines of treatment (eg, ASCENT-03, ASCENT-04) (8:51) Efficacy and tolerability of trastuzumab deruxtecan in patients with HER2-low and HER2-ultralow metastatic breast cancer (10:26) Activity and ongoing investigations of other novel agents and strategies for mTNBC (20:05) CME information and select publications

Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayBRCANegTNBC24).

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

Featuring a slide presentation and related discussion from Dr Priyanka Sharma, including the following topics: Biomarker Assays in the Identification and Prognostication of Patients with Breast Cancer (0:00) Utility of Circulating Tumor DNA in the Prognostication of Localized Breast Cancer (24:28) Treatment of HR-Positive, HER2-Negative Advanced Breast Cancer with a PI3K Mutation (29:46) Utility of Subsequent CDK4/6 Inhibitor After Disease Progression on Initial Therapy (34:57) Treatment of HER2-Low or HER2-Ultralow Metastatic Breast Cancer (40:59) Updated Data and Novel Strategies Involving Trastuzumab Deruxtecan for the Treatment of Advanced Breast Cancer (49:42) Oral Selective Estrogen Receptor Degraders for the Treatment of ER-Positive, HER2-Positive Breast Cancer (51:55) Novel Strategies Involving Antibody-Drug Conjugates and Immunotherapy for Triple-Negative Breast Cancer (58:12) CME information and select publications

Tess rang that chemo bell!! On this week's episode Tess goes into full detail about fighting breast cancer and what the past 3 months were like facing her treatment plan. She discusses everything from first steps of getting her port placed, each chemotherapy session and what tips she received that helped make her experience a little easier.When receiving the devastating news of having breast cancer at 39 years old, and then finding out it's the most scary and aggressive kind of breast cancer- Triple Negative - Tess soon learned of all the challenges and life changes she would now need to face. This can all be very overwhelming and anything I can do to educate or help others just based on my own experience, I'm willing try.Contact More Or Less With TessInstagram: @moreorlesswithtesspodcastEmail us at moreorlesswithtess@gmail.comLink to Website: https://moreorlesswithtess.buzzsprout.comThanks for listening!